A three judge panel of the United States Court of Appeals for the Federal Circuit upheld the October 2002 decision by US District Court Judge Barbara S Jones, finding that Andrx, Genpharm and Cheminor infringed AstraZeneca's patents for Prilosec (omeprazole), and that the two formulation patents are not invalid. The court also upheld the judgment that Kudco's formulation did not infringe.
AstraZeneca is pleased with the court's decision upholding the validity of the patents, again reaffirming the strength of the intellectual property.
Prilosec is a treatment for acid-related stomach disorders.